What is Biote Corp.'s market cap?

Biote Corp. (BTMD) has a market capitalization of $70.7M and trades on NASDAQ.

What is Biote Corp.'s revenue and profitability?

Biote Corp. generated $188.2M in trailing twelve-month revenue with net income of $15.6M, representing a net margin of 8.3%. Gross margin stands at 70.1%, with free cash flow of $28.9M. These figures are based on the Q1 2026 filing.

Who are Biote Corp.'s competitors?

Biote Corp.'s key competitors include Walmart, Target, Impact BioMedical, Inc., and others. These companies compete in similar markets and product categories.

Who does Biote Corp. partner with?

Biote Corp.'s notable partners include AnazaoHealth Corporation, Right Value Drug Stores, LLC (Carie Boyd’s Prescription Shop), Medline Industries, LP, and others.

What subsidiaries does Biote Corp. have?

Biote Corp.'s subsidiaries include Asteria Health, BioSana ID LLC.

Where is Biote Corp. headquartered?

Biote Corp. is headquartered in United States of America and employs approximately 194 people. It has been publicly traded since 2022.

Biote Corp.

BTMD

Biote Corp. operates a high-growth practice-building platform within the hormone optimization space, utilizing a model similar to a franchise to empower medical practitioners.

Market cap

$70.67M-48.3%

Revenue$188.2M-5.6%

Net income$15.6M-25.8%

Free cash flow$28.9M-21.9%

EPS (diluted)$0.44-26.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$44.9MMiss by $1.1M EPS$0.06Miss by $0.03

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$46.1M

EPS estimate$0.07

Financials

Q1 2026

Income statement

See full

Revenue$44.9M-8.3%

Gross profit$31.0M-14.9%

Operating income$3.2M-67.3%

Net income$2.3M-83.4%

EPS (diluted)$0.06-83.8%

Balance sheet

See full

Cash & equivalents$5.3M-87.2%

Total debt$103.4M-5.5%

Total equity-$56.1M+37.7%

Total assets$89.0M-27.8%

Cash flow

See full

Operating cash flow$3.9M-39.7%

CapEx$362.0K-77.8%

Free cash flow$3.5M-26.8%

Valuation & ratios

Valuation

See full

Market cap$70.67M-48.3%

Enterprise value$168.77M-25.3%

P/E4.5×+0.1×

P/S0.4×-0.3×

Profitability

See full

Gross margin70.1%-1.2pp

Operating margin15.4%-0.1pp

Net margin8.3%-2.3pp

FCF margin15.3%-3.2pp

Returns & leverage

See full

Current ratio1.3×-0.1×

Segments

By product

See full

Product Revenue$43.9M-6.7%

Pellet Procedures Product Revenue$31.3M-13.2%

Dietary Supplements$11.0M+19.1%

Disposable Trocars Product Revenue$1.1M-3.8%

Service Revenue$1.0M-47.1%

Competitors

By market cap

Walmart $889.24B+14.2%

Target$63.7B+31.8%

BioLife Solutions$1.5B+36.9%

Biote Corp.$70.7M-48.6%

Impact BioMedical$46.6M-34.6%

Briacell Therapeutics Corp.$30.9M+118%

GT Biopharma$12.0M+75.3%

ELA

Elevai Labs, Inc.$4.2M+33.9%

By revenue growth

BioLife Solutions+27.5%

Walmart +5.9%

Target+0.5%

Biote Corp.-5.6%

By net margin

Biote Corp.8.29%-2.3pp

Target3.24%-0.7pp

Walmart 3.13%+0.4pp

BioLife Solutions-68.71%+46.3pp

Profile

Biote Corp. operates a high-growth practice-building platform within the hormone optimization space, utilizing a model similar to a franchise to empower medical practitioners. The company provides an end-to-end solution including clinical education, proprietary decision-support software, and inventory management tools to help clinics implement personalized bioidentical hormone replacement therapy. Additionally, the company develops and sells a complementary line of private-labeled dietary supplements to address physiological deficiencies in aging populations.

Competitive position

A leading provider in the hormone optimization market with a differentiated end-to-end platform and high practitioner retention rates.

GeographiesUnited States, Puerto Rico, Mexico, Dominican Republic

Customer segmentsMedical Practitioners, Aging Population, Menopausal Women, Andropausal Men

Business modelB2B2C, Practice-building platform, Direct-to-consumer e-commerce, Wholesale

Suppliers503B outsourcing facilities, Contract supplement manufacturers, Third-party logistics (3PL) providers, Medical supply manufacturers

CustomersMedical clinics, Independent healthcare practitioners, Retail patients

CountryUnited States of America

Listed2022

Employees194.0

CEORobert C. Peterson

SectorHealthcare

IndustryMedical - Care Facilities

Websitebiote.com

FilingsSEC EDGAR

Ask your AI about Biote Corp..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biote Corp.'s market cap?: Biote Corp. (BTMD) has a market capitalization of $70.7M and trades on NASDAQ.
What is Biote Corp.'s revenue and profitability?: Biote Corp. generated $188.2M in trailing twelve-month revenue with net income of $15.6M, representing a net margin of 8.3%. Gross margin stands at 70.1%, with free cash flow of $28.9M. These figures are based on the Q1 2026 filing.
Who are Biote Corp.'s competitors?: Biote Corp.'s key competitors include Walmart, Target, Impact BioMedical, Inc., and others. These companies compete in similar markets and product categories.
Who does Biote Corp. partner with?: Biote Corp.'s notable partners include AnazaoHealth Corporation, Right Value Drug Stores, LLC (Carie Boyd’s Prescription Shop), Medline Industries, LP, and others.
What subsidiaries does Biote Corp. have?: Biote Corp.'s subsidiaries include Asteria Health, BioSana ID LLC.
Where is Biote Corp. headquartered?: Biote Corp. is headquartered in United States of America and employs approximately 194 people. It has been publicly traded since 2022.